SGLT2 Inhibitors May Predispose to Ketoacidosis

CONTEXT: Sodium glucose cotransporter 2 (SGLT2) inhibitors are antidiabetic drugs that increase urinary excretion of glucose, thereby improving glycemic control and promoting weight loss. Since approval of the first-in-class drug in 2013, data have emerged suggesting that these drugs increase the risk of diabetic ketoacidosis. In May 2015, the Food and Drug Administration issued a warning that SGLT2 inhibitors may lead to ketoacidosis. EVIDENCE ACQUISITION: Using PubMed and Google, we conducted Boolean searches including terms related to ketone bodies or ketoacidosis with terms for SGLT2 inhibitors or phlorizin. Priority was assigned to publications that shed light on molecular mechanisms whereby SGLT2…

• BS
  Bristol-Myers Squibb
• AP
  Agios Pharmaceuticals
• NI
  National Institutes of Health

  Award: MD 20892
• NI
  National Institute of Diabetes and Digestive and Kidney Diseases
• NI
  National Institute of Child Health and Human Development
• EK
  Eunice Kennedy Shriver National Institute of Child Health and Human Development